Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Next Previous
X
Search
Trial Profile

Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ublituximab (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ULTIMATE 2; ULTIMATE II
  • Sponsors TG Therapeutics Inc

    • Most Recent Events

    • 18 Sep 2024 According to TG Therapeutics, Inc media release, five-year data from the ULTIMATE I & II Phase 3 trials presented at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting
    • 18 Sep 2024 Five-year data from the ULTIMATE I & II Phase 3 trials published in the TG Therapeutics Inc Media Release
    • 05 Sep 2024 According to TG Therapeutics, Inc media release, data from both the trials (ULTIMATE I and II) in patients with relapsing forms of multiple sclerosis (RMS) to be presented at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 18 - 20, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top